Cargando…
Clinical Presentations and Outcomes of Retinoblastoma Patients in relation to the Advent of New Multimodal Treatments: A 12-Year Report from Single Tertiary Referral Institute in Thailand
PURPOSE: To investigate the clinical presentations and outcomes of retinoblastoma in relation to the advent of new multimodal treatments in Thailand. Patients and Methods. Retrospective case series. We evaluated the clinical presentation, staging, details of treatment, and treatment outcomes of reti...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7508219/ https://www.ncbi.nlm.nih.gov/pubmed/33005446 http://dx.doi.org/10.1155/2020/4231841 |
_version_ | 1783585386426007552 |
---|---|
author | Rojanaporn, Duangnate Attaseth, Taweevat Dieosuthichat, Wimwipa Leelawongs, Kitikul Pakakasama, Samart Anurathapan, Usanarat Chanthanaphak, Ekachat Singhara Na Ayudhaya, Sirintara Aroonroch, Rangsima Hongeng, Suradej |
author_facet | Rojanaporn, Duangnate Attaseth, Taweevat Dieosuthichat, Wimwipa Leelawongs, Kitikul Pakakasama, Samart Anurathapan, Usanarat Chanthanaphak, Ekachat Singhara Na Ayudhaya, Sirintara Aroonroch, Rangsima Hongeng, Suradej |
author_sort | Rojanaporn, Duangnate |
collection | PubMed |
description | PURPOSE: To investigate the clinical presentations and outcomes of retinoblastoma in relation to the advent of new multimodal treatments in Thailand. Patients and Methods. Retrospective case series. We evaluated the clinical presentation, staging, details of treatment, and treatment outcomes of retinoblastoma patients who were treated at Ramathibodi Hospital, Bangkok, Thailand, between January 1, 2007, and December 31, 2018. The log-rank test was used to explore clinical characteristics and treatment modalities that affected globe salvage and survival curves. RESULTS: This study included 124 eyes of 81 patients with retinoblastoma. Forty-three patients (53.1%) had bilateral retinoblastoma. The median age at diagnosis was 8 months (range, 1–48 months). Of 124 eyes, 9 eyes (7.3%) had extraocular retinoblastoma and 115 eyes (92.7%) had intraocular retinoblastoma, which were classified by the International Classification of Retinoblastoma (ICRB) as group A, 4 eyes (3.5%); group B, 19 eyes (16.5%); group C, 6 eyes (5.2%); group D, 31 eyes (27%); and group E, 56 eyes (47.8%). Treatment included systemic chemotherapy, intra-arterial chemotherapy, ruthenium-106 plaque brachytherapy, external beam radiation therapy, cryotherapy, transpupillary thermotherapy, subtenon chemotherapy, and intravitreal chemotherapy. At the median follow-up period of 38.4 months (range, 0.2–148.2 months), the overall globe salvage rate of intraocular retinoblastoma was 51.7%. For unilateral retinoblastoma, globe salvage rate was 37.5% (group B, 100%; group C, 100%; group D, 50%; and group E, 18.8%). For bilateral intraocular retinoblastoma, the globe salvage rate was 57.8% (group A, 100 %; group B, 94.4%; group C, 100%; group D, 64.7%; and group E, 28.2%). The overall survival rate was 93.8%. CONCLUSIONS: Recent advanced treatment modalities have improved the probability of globe salvage. However, enucleation remains an important life-saving intervention in many advanced cases. |
format | Online Article Text |
id | pubmed-7508219 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-75082192020-09-30 Clinical Presentations and Outcomes of Retinoblastoma Patients in relation to the Advent of New Multimodal Treatments: A 12-Year Report from Single Tertiary Referral Institute in Thailand Rojanaporn, Duangnate Attaseth, Taweevat Dieosuthichat, Wimwipa Leelawongs, Kitikul Pakakasama, Samart Anurathapan, Usanarat Chanthanaphak, Ekachat Singhara Na Ayudhaya, Sirintara Aroonroch, Rangsima Hongeng, Suradej J Ophthalmol Research Article PURPOSE: To investigate the clinical presentations and outcomes of retinoblastoma in relation to the advent of new multimodal treatments in Thailand. Patients and Methods. Retrospective case series. We evaluated the clinical presentation, staging, details of treatment, and treatment outcomes of retinoblastoma patients who were treated at Ramathibodi Hospital, Bangkok, Thailand, between January 1, 2007, and December 31, 2018. The log-rank test was used to explore clinical characteristics and treatment modalities that affected globe salvage and survival curves. RESULTS: This study included 124 eyes of 81 patients with retinoblastoma. Forty-three patients (53.1%) had bilateral retinoblastoma. The median age at diagnosis was 8 months (range, 1–48 months). Of 124 eyes, 9 eyes (7.3%) had extraocular retinoblastoma and 115 eyes (92.7%) had intraocular retinoblastoma, which were classified by the International Classification of Retinoblastoma (ICRB) as group A, 4 eyes (3.5%); group B, 19 eyes (16.5%); group C, 6 eyes (5.2%); group D, 31 eyes (27%); and group E, 56 eyes (47.8%). Treatment included systemic chemotherapy, intra-arterial chemotherapy, ruthenium-106 plaque brachytherapy, external beam radiation therapy, cryotherapy, transpupillary thermotherapy, subtenon chemotherapy, and intravitreal chemotherapy. At the median follow-up period of 38.4 months (range, 0.2–148.2 months), the overall globe salvage rate of intraocular retinoblastoma was 51.7%. For unilateral retinoblastoma, globe salvage rate was 37.5% (group B, 100%; group C, 100%; group D, 50%; and group E, 18.8%). For bilateral intraocular retinoblastoma, the globe salvage rate was 57.8% (group A, 100 %; group B, 94.4%; group C, 100%; group D, 64.7%; and group E, 28.2%). The overall survival rate was 93.8%. CONCLUSIONS: Recent advanced treatment modalities have improved the probability of globe salvage. However, enucleation remains an important life-saving intervention in many advanced cases. Hindawi 2020-09-10 /pmc/articles/PMC7508219/ /pubmed/33005446 http://dx.doi.org/10.1155/2020/4231841 Text en Copyright © 2020 Duangnate Rojanaporn et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Rojanaporn, Duangnate Attaseth, Taweevat Dieosuthichat, Wimwipa Leelawongs, Kitikul Pakakasama, Samart Anurathapan, Usanarat Chanthanaphak, Ekachat Singhara Na Ayudhaya, Sirintara Aroonroch, Rangsima Hongeng, Suradej Clinical Presentations and Outcomes of Retinoblastoma Patients in relation to the Advent of New Multimodal Treatments: A 12-Year Report from Single Tertiary Referral Institute in Thailand |
title | Clinical Presentations and Outcomes of Retinoblastoma Patients in relation to the Advent of New Multimodal Treatments: A 12-Year Report from Single Tertiary Referral Institute in Thailand |
title_full | Clinical Presentations and Outcomes of Retinoblastoma Patients in relation to the Advent of New Multimodal Treatments: A 12-Year Report from Single Tertiary Referral Institute in Thailand |
title_fullStr | Clinical Presentations and Outcomes of Retinoblastoma Patients in relation to the Advent of New Multimodal Treatments: A 12-Year Report from Single Tertiary Referral Institute in Thailand |
title_full_unstemmed | Clinical Presentations and Outcomes of Retinoblastoma Patients in relation to the Advent of New Multimodal Treatments: A 12-Year Report from Single Tertiary Referral Institute in Thailand |
title_short | Clinical Presentations and Outcomes of Retinoblastoma Patients in relation to the Advent of New Multimodal Treatments: A 12-Year Report from Single Tertiary Referral Institute in Thailand |
title_sort | clinical presentations and outcomes of retinoblastoma patients in relation to the advent of new multimodal treatments: a 12-year report from single tertiary referral institute in thailand |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7508219/ https://www.ncbi.nlm.nih.gov/pubmed/33005446 http://dx.doi.org/10.1155/2020/4231841 |
work_keys_str_mv | AT rojanapornduangnate clinicalpresentationsandoutcomesofretinoblastomapatientsinrelationtotheadventofnewmultimodaltreatmentsa12yearreportfromsingletertiaryreferralinstituteinthailand AT attasethtaweevat clinicalpresentationsandoutcomesofretinoblastomapatientsinrelationtotheadventofnewmultimodaltreatmentsa12yearreportfromsingletertiaryreferralinstituteinthailand AT dieosuthichatwimwipa clinicalpresentationsandoutcomesofretinoblastomapatientsinrelationtotheadventofnewmultimodaltreatmentsa12yearreportfromsingletertiaryreferralinstituteinthailand AT leelawongskitikul clinicalpresentationsandoutcomesofretinoblastomapatientsinrelationtotheadventofnewmultimodaltreatmentsa12yearreportfromsingletertiaryreferralinstituteinthailand AT pakakasamasamart clinicalpresentationsandoutcomesofretinoblastomapatientsinrelationtotheadventofnewmultimodaltreatmentsa12yearreportfromsingletertiaryreferralinstituteinthailand AT anurathapanusanarat clinicalpresentationsandoutcomesofretinoblastomapatientsinrelationtotheadventofnewmultimodaltreatmentsa12yearreportfromsingletertiaryreferralinstituteinthailand AT chanthanaphakekachat clinicalpresentationsandoutcomesofretinoblastomapatientsinrelationtotheadventofnewmultimodaltreatmentsa12yearreportfromsingletertiaryreferralinstituteinthailand AT singharanaayudhayasirintara clinicalpresentationsandoutcomesofretinoblastomapatientsinrelationtotheadventofnewmultimodaltreatmentsa12yearreportfromsingletertiaryreferralinstituteinthailand AT aroonrochrangsima clinicalpresentationsandoutcomesofretinoblastomapatientsinrelationtotheadventofnewmultimodaltreatmentsa12yearreportfromsingletertiaryreferralinstituteinthailand AT hongengsuradej clinicalpresentationsandoutcomesofretinoblastomapatientsinrelationtotheadventofnewmultimodaltreatmentsa12yearreportfromsingletertiaryreferralinstituteinthailand |